Secondary Recommendation

Dechra Pharmaceuticals - US blockbuster potential for key drug

August 2008

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Quirky TV programs such as Hollywood Pets illustrate just how far people will go to pamper their beloved household pets and Dechra (FT sector: Pharmaceuticals & Biotech), which manufactures and sells pharmaceutical products to the animal health market, is benefiting from this trend. It could even be argued that its products will survive the consumer belt tightening, a point which the healthy chart (see below) would appear to corroborate. The backbone to Dechra's business is its services division, NVS, a wholesaler distributer of pharmaceuticals, pet products, instruments and consumables. Sales split roughly 55:45 between companion animals and livestock. Since 1996 NVS has really taken a stranglehold in this Â£480m indus ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Begbies Traynor - Provider of corporate insolvency services sees ballooning demand

Connaught - Â£800m of new orders

Dechra Pharmaceuticals (November 2010)

Dechra Pharmaceuticals - US launch of Vetoryl to boost profits (February 2010)

Dechra Pharmaceuticals (November 2008)

Dechra Pharmaceuticals - Impending US drug approval could herald profit surge (April 2007)

Dechra Pharmaceuticals - Gains approach Â£1 per share (November 2005)

Dechra Pharmaceuticals (April 2005)

Dechra Pharmaceuticals - Positive AGM (December 2004)

Dechra Pharmaceuticals - New animal drug could be blockbuster (October 2004)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X